Daniel R. Karlin, MD, MA

DT-120, an optimized LSD formulation, shows lasting anxiety relief and high remission at 12 weeks, as researchers share detailed phase 2b safety insights.

Phase 2b data show DT‑120, optimized oral LSD, delivers durable GAD remission with mostly same‑day side effects; phase 3 trials advance.

Read our exclusive interview with Daniel R. Karlin, MD, MA, on the latest executive order, DT120 for the treatment of mental health disorders, and more.

DT120, a pharmaceutical-grade formulation of LSD, shows rapid, lasting anxiety relief—single dose, no therapy—with 48% remission at 12 weeks.

Definium’s CMO says FDA talks stay aligned with their plans for advancing DT120 ODT for the treatment of depression, anxiety, and now PTSD.

Explore the potential of LSD as a groundbreaking treatment for anxiety and depression.

Early phase 3 results show that a single dose of MM120 can rapidly reduce anxiety symptoms in GAD patients, with effects lasting up to 12 weeks.

With an FDA Breakthrough Therapy Designation, what are the next steps for MM-120?

MindMed has announced the first patient has been dosed in its phase 3 study Panorama.

With MM120 in phase 3 in the MindMed trial, what place do psychedelics hold in psychiatry?

MindMed announced phase 3 study of psychedelic MM120 for Generalized Anxiety Disorder.

According to the chief medical officer of MindMed, it is time to look past the history of LSD.

Generalized anxiety disorder: has it been sidelined by MDD? MM-120 is a new treatment under investigation for this disorder, making waves.